Anaphylactic inhibitors

ABSTRACT

Compounds for use as orally active anaphylactic inhibitors are disclosed. The compounds are trans-2,3b,4,5,7,8b,9,10-octahydronaphto [1,2-c:5,6-c&#39;] dipyrazoles which may be substituted in both of the pyrazole rings. Also disclosed are intermediate compounds which are the corresponding trans-2,6-bis (hydroxymethylene) decalin-1,5-diones.

This is a divisional of application Ser. No. 797,870, filed May 17, 1977, now U.S. Pat. No. 4,135,048.

BACKGROUND AND SUMMARY OF THE INVENTION

The known compound, cromolyn sodium (sodium cromoglycate, SCG) has the property that it inhibits the release of allergic mediators from sensitized tissues but does not interfere with the combination of antigen and antibody. However, this prior art compound has the disadvantage that it has been found to lack oral activity.

The present invention relates to new heterocyclic nitrogen compounds that are useful as pharmacological agents and to methods of their synthesis. More particularly, the compounds of the present invention are trans-2,3b,4,5,7,8b,9,10-octahydronaphto [1,2-c:5,6-c']dipyrazoles which may be substituted in both of the pyrazole rings. The compounds of the present invention are useful as orally active anaphylactic inhibitors for the treatment of asthmatic symptoms.

The compounds which are subject of the present invention are represented by the formula: ##STR1## wherein R is H, OH, CN, CO₂ Me, CO₂ Et, CO₂ H, CF₃, halogen, NO₂, or NH₂. These groups in general tend to increase or enhance the hydrogen-bonding capacity of the pyrazole hydrogen, a fact that is related to the biological properties of these molecules. In fact, removal of the pyrazole hydrogen by appropriate substitution eliminates completely the biological activity.

The octahydronaphto[1,2-c:5,6-c']dipyrazoles of the present invention wherein R is H, OH, CN, CO₂ Et, CO₂ Me, CO₂ H or CF₃ may be produced by reacting the corresponding trans-2,6-bis (hydroxymethylene)decalin-1,5-dione of the formula: ##STR2## wherein R is as above defined, with more than two equivalents of hydrazine in refluxing ethanol for 6 hrs.

In the case of the present compounds wherein R is halogen or NO₂, these groups are introduced after formation of the parent compound of formula (1), (R═H) by appropriate substitution. Once the NO₂ analog is obtained, the amino (NH₂) compound will also be obtainable by catalytic reduction.

The starting materials designated in formula (2) herein are also considered novel and can be obtained from known trans-decalin-1,5-dione by reaction under nitrogen with an excess of the corresponding ester of the formula:

    R-CO.sub.2 R'                                              (3)

wherein R is equal to H, OMe, OEt, CN, CO₂ Me, CO₂ Et, or CF₃ and R' is Me or Et, in the presence of sodium methoxide as catalyst and dry pyridine as solvent. The known trans-decalin-1,5-dione may be obtained by starting with commercially available 1,5-decalindiol which is subjected to oxidation under the conditions reported by W. S. Johnson et al. J. Amer. Chem. Soc., 73, 5464 (1951). As reported by these authors, the resulting dione is equilibrated to its most stable trans isomer and obtained as pure trans-decalin-1,5-dione.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The following Examples I and II describe methods of preparation of compounds having formulas (1) and (2) as shown above. Melting points were determined by means of an Electrothermal capillary melting point apparatus and they are uncorrected. A Perkin-Elmer Model 727 infrared spectrophotometer was employed for ir spectra, using either nujol mulls or chloroform solutions. A Varian Associates Model EM-360 analytical nmr spectrometer was used for nmr spectra. Ultraviolet spectra were recorded on a Beckman Model 25 spectrophotometer utilizing 1 cm path cells. Mass spectra were obtained in a Hitachi Perkin-Elmer RMU-6H instrument at 70 eV.

EXAMPLE I

Example of a compound of formula (2) wherein R═H. trans-2,6-Bis(hydroxymethylene)decalin-1,5-dione. A mixture of 1.66 g (10 mmole) of trans-decalin-1,5-dione, 2.16 g (40 mmole) of NaOCH₃, 9.2 ml (130 mmole) of ethyl formate, and 70 ml of dry pyridine was stirred under nitrogen at room temperature for 21 hr. After the mixture was adjusted to a pH between 5 and 6 with the aid of 51 ml of AcOH and 471 ml of water, it was extracted with benzene several times. The benzene layers were thoroughly washed with water and then were extracted with 2% KOH solution. The basic extracts were washed with ether and then after reacidification with AcOH they were thoroughly extracted again with benzene. The benzene extracts were dried (Na₂ SO₄) and then were reduced to dryness to give 2 g (90%) of crude product. Recrystallization from ethanol afforded trans-2,6-Bis(hydroxymethylene)decalin-1,5-dione as a fine yellow powder, mp 155°- 157°; ir (nujol) 1640 and 1570 cm⁻¹ ; nmr (CDCl₃)δ2.3 (broad multiplet, 10), 9.00 (s,2), and 14.50 (s,2); mass spectrum m/e 222 (M⁺.).

Anal. Calcd. for C₁₂ H₁₄ O₄ : C, 64.85; H, 6.35. Found: C, 64.69; H, 6.38.

EXAMPLE II

Example of a compound of formula (1) wherein R═H.

trans-2,3b,4,5,7,8b,9,10-Octahydronaphto[1,2-c:5,6-c']dipyrazole. A mixture of 1.11 g (5 mmole) of trans-2,6-Bis(hydroxymethylene) decaline-1,5-dione, 1 ml (c.a. 0.02 mole) of hydrazine hydrate and50 ml of ethanol was refluxed for 6 hr. After the total volume was reduced to about half, the compound slowly precipitated at room temperature. The solid was collected, dried and recrystallized twice from ethanol to yield 0.7 g (65%) of trans-2,3b,4,5,7,8b,9,10-Octahydronaphto[1,2-c:5,6-c']dipyrazole as very fine off-white crystals, mp 300°dec; ir (nujol) 3200 (s, broad), 1600 (w), 1580 (w), 1340 (m), 1180 (m), 1100 (m), 1080 (m) 980 (s), 880 (m), and 820 (m); nmr (DMSO-d₆)δ7.40 and 7.30 (singlets, 2), and 12.6 (broad singlet, 2); mass spectrum m/e 214 (M³⁰.).

Anal. Calcd for C₁₂ H₁₄ N₄ : C, 67.26; H, 6.59; N, 26.15.

Found: C, 67.09; H, 6.48; N, 26.10.

BIOLOGICAL ACTIVITY

The compound of formula (1), R═H, has been tested extensively. The tests performed for PCA (Passive Cutaneous Anaphylaxis) are rather simple and many references in the literature can be found as, for example, in J. Goose and A. M. J. N. Blair, Immunology, 16, 749 (1969). The method basically includes injecting rats intracutaneously on their shaved backs with sera (0.5 ml) from rats immunized with egg albumin and Bordetella pertusis vaccine. After the initial injections (24 hr) test drugs are administered p.o. at a dose of 100 mg/kg. One hour later, 1 ml of 0.5% solution of Evans Blue dye and 8 mg of egg albumin are injected iv. After an additional 140 minutes the animals are sacrificed, the skins on their backs is turned back, and the wheal sizes are measured. Reduction of the wheal size of the treated animals is expressed as a percent inhibition in relation to the control group which receives no drug. The results of the use of the compound of formula (1), R═H, compared to those obtained with sodium cromoglycate (SCG) are shown in Table I.

                  TABLE I                                                          ______________________________________                                                                         Bio-                                                       Route Of            logical                                                    Admini-             Acti-                                          Compound    stration  Dose      vity  Remarks                                  ______________________________________                                         Formula (1), R=H                                                                           P.O.      100 mg/kg 67                                             Formula (1), R=H                                                                           P.O.       50 mg/kg 54    approx.                                                                        MED.                                     Formula (1), R=H                                                                           P.O.       25 mg/kg 40                                             SCG.sup.a   I.P.       60 mg/kg 60                                             SCG         I.V.       5 mg/kg  75    ED 100                                   ______________________________________                                          .sup.a SCG = Sodium Cromoglycate                                         

Systemic anaphylaxis was also prevented at 50 mg/kg in mice one hour after oral administration indicating that the compound is not specific for reaginic antibody reactions and yet no conventional antihistaminic or antiserotonin activity was detected in vitro at a dose of 10 mcg/ml. The results comparing the activity of the compound of formula (1), R═H, against that of phenyltoxolamine are summarized in Table II.

                  TABLE II                                                         ______________________________________                                                                        Bio-                                                        Route of           logical.sup.b                                               Admini-            Acti-                                           Compound    stration  Dose     vity   Remarks                                  ______________________________________                                         Phenyltoxolamine                                                                           P.O.      50 mg/kg 0      ED 100                                   Formula (1), R=H                                                                           P.O.      50 mg/kg 0      MED                                      Formula (1), R=H                                                                           P.O.      25 mg/kg 1                                               ______________________________________                                          .sup.b Critical biological response = 0 (less than 1/3 of the mice exhibi      anaphylaxis after one hour).                                             

It is thought that the invention and many of its attendant advantages will be understood from the foregoing description, and it will be apparent that various changes may be made in the invention as described herein without departing from the spirit and scope of the invention or sacrificing its material advantages, the forms hereinbefore described being merely preferred embodiments thereof. 

It is claimed:
 1. A method for the treatment of asthmatic symptoms which comprises orally administering to an animal in need of such treatment an anaphylactic inhibiting effective amount of a compound of the formula ##STR3## wherein R is H, OH, CN, CO₂ Me, CO₂ Et, CO₂ H, CF₃, halogen, NO₂ or NH₂.
 2. The method of claim 1 wherein R is H. 